The DOI matches its Crossref record; 42 of the 42 references it cites were found in a registry or an index.
Effects of Oral Ibandronate Administered Daily or Intermittently on Fracture Risk in Postmenopausal Osteoporosis
Open accessAbstract
Oral daily (2.5 mg) and intermittent ibandronate (between-dose interval of >2 months), delivering a similar cumulative exposure, were evaluated in 2946 osteoporotic women with prevalent vertebral fracture. Significant reduction in incident vertebral fracture risk by 62% and 50%, respectively, was shown after 3 years. This is the first study to prospectively show antifracture efficacy for the intermittent administration of a bisphosphonate. Introduction: Bisphosphonates are important therapeutics in postmenopausal osteoporosis. However, they are currently associated with stringent dosing instructions that may impair patient compliance and hence therapeutic efficacy. Less frequent, intermittent administration may help to overcome these deficiencies. This study assessed the efficacy and safety of oral ibandronate administered either daily or intermittently with a dose-free interval of >2 months. Materials and Methods: This randomized, double-blind, placebo-controlled, parallel-group study enrolled 2946 postmenopausal women with a BMD T score ≤ −2.0 at the lumbar spine in at least one vertebra (L1-L4) and one to four prevalent vertebral fractures (T4-L4). Patients received placebo or oral ibandronate administered either daily (2.5 mg) or intermittently (20 mg every other day for 12 doses every 3 months). Results and Conclusions: After 3 years, the rate of new vertebral fractures was significantly reduced in patients receiving oral daily (4.7%) and intermittent ibandronate (4.9%), relative to placebo (9.6%). Thus, daily and intermittent oral ibandronate significantly reduced the risk of new morphometric vertebral fractures by 62% (p = 0.0001) and 50% (p = 0.0006), respectively, versus placebo. Both treatment groups also produced a statistically significant relative risk reduction in clinical vertebral fractures (49% and 48% for daily and intermittent ibandronate, respectively). Significant and progressive increases in lumbar spine (6.5%, 5.7%, and 1.3% for daily ibandronate, intermittent ibandronate, and placebo, respectively, at 3 years) and hip BMD, normalization of bone turnover, and significantly less height loss than in the placebo group were also observed for both ibandronate regimens. The overall population was at low risk for osteoporotic fractures. Consequently, the incidence of nonvertebral fractures was similar between the ibandronate and placebo groups after 3 years (9.1%, 8.9%, and 8.2% in the daily, intermittent, and placebo groups, respectively; difference between arms not significant). However, findings from a posthoc analysis showed that the daily regimen reduces the risk of nonvertebral fractures (69%; p = 0.012) in a higher-risk subgroup (femoral neck BMD T score < −3.0). In addition, oral ibandronate was well tolerated. Oral ibandronate, whether administered daily or intermittently with an extended between-dose interval of >2 months, is highly effective in reducing the incidence of osteoporotic fractures in postmenopausal women. This is the first time that significant fracture efficacy has been prospectively shown with an intermittently administered bisphosphonate in the overall study population of a randomized, controlled clinical trial. Thus, oral ibandronate holds promise as an effective and convenient alternative to current bisphosphonate therapies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“Ibandronate reduces the incidence of vertebral fractures by about 50 % over 3 years, but reduction in risk of nonvertebral fracture with ibandronate has not been documented [50].”
From Clinician’s Guide to Prevention and Treatment of Osteoporosis (2014) · cites this paper as [50]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“This is true for fracture patients with BMD in both the low bone mass and osteoporosis range [49–58].”
From Clinician’s Guide to Prevention and Treatment of Osteoporosis (2014) · cites this paper as [50]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“There are abundant data that patients with spine and hip fractures will have reduced fracture risk if treated with pharmacologic therapy.”
From Clinician’s Guide to Prevention and Treatment of Osteoporosis (2014) · cites this paper as [50]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Ibandronate reduces the incidence of vertebral fractures by about 50 % over 3 years, but reduction in risk of nonvertebral fracture with ibandronate has not been documented [50].”
From Clinician’s Guide to Prevention and Treatment of Osteoporosis (2014) · cites this paper as [50]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Black, D. M., Cummings, S. R., Karpf, D. B., Cauley, J. A., Thompson, D. E., Nevitt, M. C., Bauer, D. C., Genant, H. K., Haskell, W. L., Marcus, R., et al. (1996) · The Lancet · doi:10.1016/s0140-6736(96)07088-2 · Cited by 3,846
Liberman, U. A., Weiss, S. R., Bröll, J., Minne, H. W., Quan, H., Bell, N. H., Rodriguez-Portales, J. A., Downs, R. W., Dequeker, J., Favus, M. J., et al. (1995) · New England Journal of Medicine · doi:10.1056/nejm199511303332201 · Cited by 2,276
Self-citationEffect of Risedronate on the Risk of Hip Fracture in Elderly Women
McClung, M. R., Geusens, P., Miller, P. D., Zippel, H., Bensen, W. G., Roux, C., Adami, S., Fogelman, I., Diamond, T., Eastell, R., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200102013440503 · Cited by 1,918
Self-citationReginster, J.-Y., Minne, H. W., Sorensen, O. H., Hooper, M., Roux, C., Brandi, M. L., Lund, B., Ethgen, D., Pack, S., Roumagnac, I., et al. (2000) · Osteoporosis International · doi:10.1007/s001980050010 · Cited by 1,580
Fracture Risk Reduction with Alendronate in Women with Osteoporosis: The Fracture Intervention Trial
Black, D. M., Thompson, D. E., Bauer, D. C., Ensrud, K., Musliner, T., Hochberg, M. C., Nevitt, M. C., Suryawanshi, S., & Cummings, S. R. (2000) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.85.11.6953 · Cited by 982
Noninvasive assessment of bone mineral and structure: State of the art
Genant, H. K., Engelke, K., Fuerst, T. P., Glüer, C., Grampp, S., Harris, S. T., Jergas, M. D., Lang, T., Lü, Y., Majumdar, S., et al. (1996) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.5650110602 · Cited by 948
Intermittent Cyclical Etidronate Treatment of Postmenopausal Osteoporosis
Watts, N. B., Harris, S. T., Genant, H. K., Wasnich, R. D., Miller, P. D., Jackson, R. D., Licata, A. A., Ross, P. D., Woodson, G. C., Yanover, M., et al. (1990) · New England Journal of Medicine · doi:10.1056/nejm199007123230201 · Cited by 947
Self-citationStorm, T., Thamsborg, G., Steiniche, T., Genant, H. K., & Sørensen, O. H. (1990) · New England Journal of Medicine · doi:10.1056/nejm199005033221803 · Cited by 926
Research works printed but not linked: 4
- Melton, 1991, Long-term fracture risk prediction with bone mineral measurements made at various skeletal sites, J Bone Miner Res, 6, S136
- Kendler, 2002, Patient preference of once weekly or daily administration of alendronate (Fosamax) for osteoporosis: a randomized cross-over study, Osteoporos Int, 13, S32
- Palmisano, 2002, Preference study of alendronate 70 mg once weekly and alendronate 10 mg once daily in postmenopausal women with osteoporosis, Osteoporos Int, 13, S36
- Kiel, 1995, Assessing vertebral fractures. National Osteoporosis Foundation Working Group on Vertebral Fractures, J Bone Miner Res, 10, 518
Cited by
Sorted by citations
Items 501–600 of 999
Bone Health in Women with Early-Stage Breast Cancer
Chlebowski, R. T. (2005) · Clinical Breast Cancer · doi:10.3816/cbc.2005.s.002 · Cited by 21
Anabolic treatments for osteoporosis in postmenopausal women
Hassan, N., Gregson, C. L., & Tobias, J. H. (2021) · Faculty Reviews · doi:10.12703/r/10-44 · Cited by 22
Felsenberg, D., Bock, O., Börst, H., Armbrecht, G., Beller, G., Degner, C., Stephan-Oelkers, M., Schacht, E., Mazor, Z., Hashimoto, J., et al. (2011) · PubMed · Cited by 20
Self-citationHagino, H., Yoshida, S., Hashimoto, J., Matsunaga, M., Tobinai, M., & Nakamura, T. (2014) · Calcified Tissue International · doi:10.1007/s00223-014-9927-7 · Cited by 20
Yates, J. (2012) · Osteoporosis International · doi:10.1007/s00198-012-2179-3 · Cited by 20
Tanaka, M., Mori, H., Kayasuga, R., Ochi, Y., Kawada, N., Yamada, H., & Kishikawa, K. (2008) · Bone · doi:10.1016/j.bone.2008.07.002 · Cited by 20
Monoclonal antibodies for the treatment of osteoporosis
Lewiecki, E. M. (2012) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2012.740006 · Cited by 20
Nakashima, D., Kanchiku, T., Nishida, N., Ito, S., Junji, O. H. G. I., Suzuki, H., Imajo, Y., Funaba, M., Chen, X., & Taguchi, T. (2018) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2018.5848 · Cited by 20
Algorithm for the Management of Osteoporosis
Hamdy, R. C., Baim, S., Broy, S. B., Lewiecki, E. M., Morgan, S. L., Tanner, S. B., & Williamson, H. F. (2010) · Southern Medical Journal · doi:10.1097/smj.0b013e3181f0e8d6 · Cited by 20
Clinical challenges in the management of osteoporosis
Vondracek, S. F. (2008) · Clinical Interventions in Aging · doi:10.2147/cia.s2539 · Cited by 21
Muratore, M., Quarta, E., Quarta, L., Calcagnile, F., Grimaldi, A., Orgiani, M. A., Marsilio, A., & Rollo, G. (2012) · Europe PMC (PubMed Central) · Cited by 20
Medical treatment of severe osteoporosis including new concept of advanced severe osteoporosis
Choi, H. S., Park, S. Y., Kim, Y. M., Kim, S. H., Kim, K. M., & Chung, Y. (2016) · Osteoporosis and Sarcopenia · doi:10.1016/j.afos.2016.02.003 · Cited by 20
Updates on mechanism of action and clinical efficacy of risedronate in osteoporosis
Nuti, R. (2014) · Clinical cases in mineral and bone metabolism · doi:10.11138/ccmbm/2014.11.3.208 · Cited by 20
Miller, P. D. (2007) · Current Medical Research and Opinion · doi:10.1185/030079908x253681 · Cited by 20
Fardellone, P., Cortet, B., Legrand, É., Bresse, X., Bisot-Locard, S., Vigneron, A.-M., & Béresniak, A. (2010) · Joint Bone Spine · doi:10.1016/j.jbspin.2009.04.009 · Cited by 20
McClung, M. R. (2006) · Arquivos Brasileiros de Endocrinologia & Metabologia · doi:10.1590/s0004-27302006000400018 · Cited by 20
Ten-year fracture risk predicted by proximal femur Hounsfield units
Christensen, D. L., Nappo, K. E., Wolfe, J. A., Tropf, J. G., Berge, M., Wheatley, B. M., Saxena, S., Yow, B. G., & Tintle, S. M. (2020) · Osteoporosis International · doi:10.1007/s00198-020-05477-y · Cited by 19
A summary of the Russian clinical guidelines on the diagnosis and treatment of osteoporosis
Belaya, Z. E., Rozhinskaya, L. Y., Dedov, I. I., Drapkina, O. M., Fadeev, V. V., Golounina, O. O., Lesnyak, O. M., Mamedova, E., Mel'nichenko, G. A., Petraikin, A. V., et al. (2023) · Osteoporosis International · doi:10.1007/s00198-022-06667-6 · Cited by 24
Ong, T. I. W., Lim, L., Chan, S. P., Chee, W. S. S., Ch’ng, A. S. H., Chong, E. G. M., Damodaran, P., Hew, F. L., Ibrahim, L., Khor, H. M., et al. (2023) · Osteoporosis and Sarcopenia · doi:10.1016/j.afos.2023.06.002 · Cited by 19
Zambon, A., Baio, G., Mazzaglia, G., Merlino, L. G., & Corrao, G. (2008) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.1530 · Cited by 19
N-Phenacylthiazolium Bromide Reduces Bone Fragility Induced by Nonenzymatic Glycation
Bradke, B. S., & Vashishth, D. (2014) · PLoS ONE · doi:10.1371/journal.pone.0103199 · Cited by 19
Kim, S. H., Choi, H. S., Rhee, Y., Kim, K. J., & Lim, S.-K. (2010) · Osteoporosis International · doi:10.1007/s00198-010-1298-y · Cited by 19
Osteoporosis prescribing trends in primary care: a population-based retrospective cohort study
Wang, L., Tracy, C. S., Moineddin, R., & Upshur, R. E. G. (2012) · Primary Health Care Research & Development · doi:10.1017/s1463423612000114 · Cited by 19
II Consenso Colombiano para el Manejo de la Osteoporosis Posmenopáusica
Orjuela, A. M., Rosero, O., Rueda-Plata, P. N., Escobar, F. S., Chalem, M., Reyes, M., Román-Gonzaléz, A., Lozano, A. T., Talero, A. P., Beltz, C. R., et al. (2018) · Revista Colombiana de Reumatología · doi:10.1016/j.rcreu.2018.02.006 · Cited by 29
Treating Osteoporosis with Bisphosphonates and Addressing Adherence
Chesnut, C. H. (2006) · Drugs · doi:10.2165/00003495-200666100-00004 · Cited by 19
Self-citationDenosumab – an emerging treatment for postmenopausal osteoporosis
Lewiecki, E. M. (2010) · Expert Opinion on Biological Therapy · doi:10.1517/14712591003604708 · Cited by 18
Importance of Calcium Co-Medication in Bisphosphonate Therapy of Osteoporosis
Ringe, J. D., van der Geest, S. A. P., & M??ller, G. (2006) · Drugs & Aging · doi:10.2165/00002512-200623070-00003 · Cited by 19
Heidenreich, A., & Ohlmann, C. (2004) · Expert Review of Anticancer Therapy · doi:10.1586/14737140.4.6.991 · Cited by 19
Review of Treatment Modalities for Postmenopausal Osteoporosis
Hamdy, R. C., Chesnut, C. H., Gass, M. L. S., Holick, M. F., Leib, E. S., Lewiecki, M. E., Maricic, M. J., & Watts, N. B. (2005) · Southern Medical Journal · doi:10.1097/01.smj.0000184921.53062.bf · Cited by 19
Self-citationBriot, K., Cortet, B., Thomas, T., Audran, M., Blain, H., Breuil, V., Chapuis, L., Chapurlat, R. D., Fardellone, P., Féron, J.-M., et al. (2012) · Revue du Rhumatisme · doi:10.1016/j.rhum.2012.02.006 · Cited by 18
Catalano, A., Bellone, F., Santoro, D., Schwarz, P., Gaudio, A., Basile, G., Sottile, M. C., Stoian, S. A., Corica, F., & Morabito, N. (2021) · Nutrients · doi:10.3390/nu13061878 · Cited by 18
Enhanced Oral Absorption of Ibandronate via Complex Formation with Bile Acid Derivative
Park, J. W., Hwang, S. R., Jeon, O., Moon, H. T., & Byun, Y. (2012) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.23413 · Cited by 18
Brandi, M., & Cavalli, L. (2012) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.s7688 · Cited by 18
Eastell, R. (2007) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2007.05.017 · Cited by 18
Bonnick, S. L. (2011) · Journal of Clinical Densitometry · doi:10.1016/j.jocd.2011.07.006 · Cited by 18
Emerging anabolic agents in the treatment of osteoporosis
Lovato, C. M., & Lewiecki, E. M. (2017) · Expert Opinion on Emerging Drugs · doi:10.1080/14728214.2017.1362389 · Cited by 18
Osteopenia: A Diagnostic and Therapeutic Challenge
Lems, W. F., Raterman, H. G., van den Bergh, J. P., Bijlsma, H. W. J., Valk, N. K., Zillikens, M. C., & Geusens, P. (2011) · Current Osteoporosis Reports · doi:10.1007/s11914-011-0062-3 · Cited by 18
Milan Meloun, A., Ferenčíková, Z., Netolická, L., & Pekárek, T. (2011) · Journal of Chemical & Engineering Data · doi:10.1021/je200512e · Cited by 18
Weekly versus monthly drug regimens: 1-year compliance and persistence with bisphosphonate therapy
Gold, D. T., Trinh, H., & Safi, W. (2009) · Current Medical Research and Opinion · doi:10.1185/03007990903035604 · Cited by 18
Once-monthly dosing: An effective step forward
Reid, D. M. (2006) · Bone · doi:10.1016/j.bone.2006.01.153 · Cited by 17
Croom, K. F., & Scott, L. J. (2006) · Drugs · doi:10.2165/00003495-200666120-00005 · Cited by 18
Rackoff, P. J. (2009) · Clinical Interventions in Aging · doi:10.2147/cia.s4080 · Cited by 18
Corrao, G., Biffi, A., Porcu, G., Ronco, R., Adami, G., Alvaro, R., Bogini, R., Caputi, A. P., Cianferotti, L., Frediani, B., et al. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1137671 · Cited by 18
Yeap, S. S., Hew, F. L., Damodaran, P., Chee, W. S. S., Lee, J. K., Goh, E. M. L., Mumtaz, M., Lim, H. H., & Chan, S. P. (2016) · Osteoporosis and Sarcopenia · doi:10.1016/j.afos.2016.02.004 · Cited by 20
Miller, P. D., Ward, P., Pfister, T., Leigh, C., & Body, J. (2008) · PubMed · Cited by 17
Evaluation of a program of integrated care to reduce recurrent osteoporotic fractures
Goltz, L., Degenhardt, G. A., Maywald, U., Kirch, W., & Schindler, C. (2013) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.3399 · Cited by 17
The Osteoporosis Needs of Patients With Wrist Fracture
Bogoch, E. R., Elliot-Gibson, V. I. M., Escott, B. G., & Beaton, D. (2008) · Journal of Orthopaedic Trauma · doi:10.1097/bot.0b013e31815e9ff7 · Cited by 17
Management of difficult osteoporosis
Russell, L. (2018) · Best Practice & Research Clinical Rheumatology · doi:10.1016/j.berh.2019.04.002 · Cited by 17
Biochemical Markers of Bone Turnover in Osteoporosis
Szulc, P., & Bauer, D. C. (2013) · Elsevier eBooks · doi:10.1016/b978-0-12-415853-5.00067-4 · Cited by 22
Bisphosphonates for Breast Cancer: Questions Answered, Questions Remaining
Layman, R. M., Olson, K. B., & Poznak, C. H. V. (2007) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2007.03.004 · Cited by 17
Biochemical Markers of Bone Turnover
CAREY, J. J., Licata, A. A., & Delaney, M. F. (2006) · Clinical Reviews in Bone and Mineral Metabolism · doi:10.1385/bmm:4:3:197 · Cited by 18
Kreck, S., Klaus, J., Leidl, R., von Tirpitz, C., Konnopka, A., Matschinger, H., & König, H. (2008) · PharmacoEconomics · doi:10.2165/00019053-200826040-00004 · Cited by 17
Treatment of Osteoporosis: All the Questions We Still Cannot Answer
Laroche, M. (2008) · The American Journal of Medicine · doi:10.1016/j.amjmed.2008.03.048 · Cited by 17
Tankó, L. B., & Christiansen, C. (2007) · Elsevier eBooks · doi:10.1016/b978-012369443-0/50036-3 · Cited by 17
Self-citationOsteoporosis: From Bone Biology to Individual Treatment Decision
Gonçalves, M. J., Rodrigues, A. M., Canhão, H. M., & Fonseca, J. E. (2013) · Acta Médica Portuguesa · doi:10.20344/amp.4271 · Cited by 16
Kaštelan, D., Lozo, P., Stamenković, D., Miškić, B., Vlak, T., Kolak, Ž., Ahić, J. M., Altabas, V., Orlić, Ž. C., & Koršić, M. (2008) · Clinical Rheumatology · doi:10.1007/s10067-008-1039-1 · Cited by 16
Herrero, S., & Picó, Y. (2016) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2016.02.053 · Cited by 16
Advances in osteoporosis from 1970 to 2018
Gallagher, J. C. (2018) · Menopause The Journal of The North American Menopause Society · doi:10.1097/gme.0000000000001263 · Cited by 16
Summary of the draft federal clinical guidelines for osteoporosis
Belaya, Z. E., Rozhinskaya, L. Y., Grebennikova, T. A., Kanis, J. А., Pigarova, E. A., Rodionova, S. S., Toroptsova, N. V., Nikitinskaya, O. A., Skripnikova, I. A., Drapkina, O. M., et al. (2021) · Osteoporosis and Bone Diseases · doi:10.14341/osteo12710 · Cited by 17
Iida, H., Sakai, Y., Seki, T., Watanabe, T., Wakao, N., Matsui, H., & Imagama, S. (2022) · Osteoporosis International · doi:10.1007/s00198-021-06264-z · Cited by 16
Bone turnover markers to monitor oral bisphosphonate therapy
ASHCHERKIN, N., Patel, A. A., Algeciras‐Schimnich, A., & Doshi, K. B. (2023) · Cleveland Clinic Journal of Medicine · doi:10.3949/ccjm.90a.22002 · Cited by 19
Pharmacological treatment of osteoporosis for people over 70
Álvarez, M. J. M., & Díaz Curiel, M. (2007) · Aging Clinical and Experimental Research · doi:10.1007/bf03324697 · Cited by 16
de Lusignan, S., van Vlymen, J. N., Hague, N., & Dhoul, N. (2006) · Osteoporosis International · doi:10.1007/s00198-006-0188-9 · Cited by 16
Dimai, H. P., Pietschmann, P., Resch, H., Preisinger, E., Fahrleitner‐Pammer, A., Dobnig, H., & Klaushofer, K. (2009) · Wiener Medizinische Wochenschrift · doi:10.1007/s10354-009-0656-x · Cited by 16
Kamienski, M. C., Tate, D. G., & Vega, C. M. (2011) · Orthopaedic Nursing · doi:10.1097/nor.0b013e318219ab9d · Cited by 16
Clarke, B. L. (2007) · Yearbook of Endocrinology · doi:10.1016/s0084-3741(08)70152-5 · Cited by 16
Stuss, M., Sewerynek, E., Król, I., Stępień-Kłos, W., & Jędrzejczyk, S. (2016) · Endokrynologia Polska · doi:10.5603/ep.a2016.0014 · Cited by 17
Improved GI Tolerability with Monthly Ibandronate in Women Previously Using Weekly Bisphosphonates
Binkley, N., Martens, M. G., Silverman, S. L., Derman, R. J., Greenwald, M., Kohles, J. D., & Bachmann, G. A. (2009) · Southern Medical Journal · doi:10.1097/smj.0b013e31819ed0dd · Cited by 16
Boonen, S. (2007) · Bone · doi:10.1016/j.bone.2007.03.003 · Cited by 16
Use of intravenous bisphosphonates in osteoporosis
Civitelli, R., Napoli, N., & Armamento‐Villareal, R. (2007) · Current Osteoporosis Reports · doi:10.1007/bf02938617 · Cited by 16
Lewiecki, E. M. (2006) · Current Opinion in Endocrinology & Diabetes · doi:10.1097/med.0b013e32801061f2 · Cited by 16
A rational approach to evidence gaps in the management of osteoporosis
Rosen, C. J., & Brown, S. A. (2005) · The American Journal of Medicine · doi:10.1016/j.amjmed.2005.06.002 · Cited by 15
Migliorini, F., Maffulli, N., Colarossi, G., Filippelli, A., Memminger, M. K., & Conti, V. (2025) · European journal of medical research · doi:10.1186/s40001-025-02412-x · Cited by 16
Jeon, I., Park, S. B., Moon, B. J., Choi, M., Kuh, S. U., & Kim, J. (2024) · Neurospine · doi:10.14245/ns.2347256.628 · Cited by 15
Ito, M., Tobinai, M., Yoshida, S., Hashimoto, J., & Nakamura, T. (2015) · Journal of Bone and Mineral Metabolism · doi:10.1007/s00774-015-0723-x · Cited by 15
Caires, E. L. P., Bezerra, M. C., Junqueira, A. F. T. D. A., Fontenele, S. M. D. A., Andrade, S. C. D. A., & d’Alva, C. B. (2017) · Revista Brasileira de Reumatologia (English Edition) · doi:10.1016/j.rbre.2017.01.001 · Cited by 15
Boonen, S., Kay, R., Cooper, C. C., Haentjens, P., Vanderschueren, D., Callewaert, F., Milisen, K., & Ferrari, S. (2009) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2009.02206.x · Cited by 15
Hip fracture rates and bisphosphonate consumption in Spain. An ecologic study
Arias, L. H. M., Lobato, C. T., García-Ortega, P., Paredes, J. R., Escudero, A., Sáinz-Gil, M., Salado, I., Velasco, V., & Carvajal, A. (2012) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-012-1337-z · Cited by 15
Ramchand, S. K., David, N. L., Leder, B. Z., & Tsai, J. N. (2019) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgz163 · Cited by 15
Frampton, J. E., & Perry, C. M. (2008) · Drugs · doi:10.2165/0003495-200868180-00011 · Cited by 15
Newer drug treatments: Their effects on fracture prevention
Geusens, P., & Reid, D. M. (2005) · Best Practice & Research Clinical Rheumatology · doi:10.1016/j.berh.2005.07.003 · Cited by 15
Current challenges in the treatment of osteoporosis: an opportunity for bazedoxifene
Reginster, J., Ferrari, S., & Hadji, P. (2014) · Current Medical Research and Opinion · doi:10.1185/03007995.2014.890927 · Cited by 15
Leizaola‐Cardesa, I. O., Aguilar‐Salvatierra, A., González‐Jaranay, M., Moreu, G., Sala-Romero, M.-J., & Moreno, G. G. (2016) · Medicina oral, patología oral y cirugía bucal · doi:10.4317/medoral.20927 · Cited by 15
Bisphosphonates: Pharmacology and Use in the Treatment of Osteoporosis
Miller, P. D. (2008) · Elsevier eBooks · doi:10.1016/b978-012370544-0.50076-8 · Cited by 15
Bisphosphonate antifracture efficacy
Adami, S. (2007) · Bone · doi:10.1016/j.bone.2007.08.005 · Cited by 14
Intermittent Bisphosphonate Therapy in Postmenopausal Osteoporosis
Reginster, J., Malaise, O., Neuprez, A., Jouret, V.-E., & Close, P. (2007) · Drugs & Aging · doi:10.2165/00002512-200724050-00001 · Cited by 15
Prevention of postmenopausal osteoporosis with pharmacological therapy: practice and possibilities
Reginster, J. (2004) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.2004.01292.x · Cited by 15
Bone Health in Idiopathic Inflammatory Myopathies: Diagnosis and Management
Vincze, A., Gaál, J., & Griger, Z. (2021) · Current Rheumatology Reports · doi:10.1007/s11926-021-01016-8 · Cited by 14
Schini, M., Vilaça, T., Vittinghoff, E., Lui, L., Ewing, S. K., Thompson, A. R., Bauer, D. C., Bouxsein, M., Black, D. M., & Eastell, R. (2024) · Journal of Bone and Mineral Research · doi:10.1093/jbmr/zjae040 · Cited by 15
The use of bisphosphonates in women: when to use and when to stop
Gatti, D., Adami, S., Viapiana, O., & Rossini, M. (2015) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2015.1087506 · Cited by 14
Kim, J., Kim, K. M., Lim, S. K., Kang, M.-I., Baek, K., & Min, Y. (2022) · BMC Endocrine Disorders · doi:10.1186/s12902-022-01010-w · Cited by 13
Porcu, G., Biffi, A., Ronco, R., Adami, G., Alvaro, R., Bogini, R., Caputi, A. P., Frediani, B., Gatti, D., Gonnelli, S., et al. (2023) · Journal of Endocrinological Investigation · doi:10.1007/s40618-023-02222-0 · Cited by 14
Antiresorptive Therapies for Osteoporosis
Weinerman, S. A., & Usera, G. L. (2015) · Oral and Maxillofacial Surgery Clinics of North America · doi:10.1016/j.coms.2015.07.001 · Cited by 14
Sunyecz, J. A. (2008) · Clinical Interventions in Aging · doi:10.2147/cia.s2496 · Cited by 14
McIntyre, C., Schmidt, J., Castelli, M., & Bittner, B. (2011) · Journal of Drug Delivery Science and Technology · doi:10.1016/s1773-2247(11)50084-x · Cited by 14
Kimoto, A., Tanaka, M., Nozaki, K., Mori, M., Fukushima, S., Mori, H., Shiroya, T., & Nakamura, T. (2013) · Bone · doi:10.1016/j.bone.2013.02.013 · Cited by 14
Management of Osteoporosis Among Home Health and Long-Term Care Patients with a Prior Fracture
Warriner, A. H., Outman, R. C., Saag, K. G., Berry, S. D., Colon-Emeric, C. S., Flood, K. L., Lyles, K. W., Tanner, S. B., Watts, N. B., & Curtis, J. R. (2009) · Southern Medical Journal · doi:10.1097/smj.0b013e31819bc1d3 · Cited by 14
Chung, Y., Lim, S.-K., Chung, H.-Y., Lee, I. K., Park, I., Kim, G.-S., Min, Y., Kang, M.-I., Chung, D.-J., Kim, Y.-K., et al. (2009) · Calcified Tissue International · doi:10.1007/s00223-009-9294-y · Cited by 14
Kearns, A. E., & Kallmes, D. F. (2008) · American Journal of Neuroradiology · doi:10.3174/ajnr.a1176 · Cited by 15
de Paula, F. J. A., Black, D. M., & Rosen, C. J. (2016) · Elsevier eBooks · doi:10.1016/b978-0-323-29738-7.00029-0 · Cited by 14
Metadata
- Authors
- Chesnut, C. H., Skag, A., Christiansen, C., Recker, R., Stakkestad, J. A., Hoiseth, A., Felsenberg, D., Huss, H., Gilbride, J., Schimmer, R. C., Delmas, P. D., & (BONE), F. T. O. I. O. V. F. T. I. N. A. A. E.
- Affiliations
- University of Washington (US)
- Center for Clinical Trials, Bergen, Norway
- Center for Clinical & Basic Research (DK)
- Creighton University (US)
- CECOR AS, Haugesund, Norway
- Oslo Department, Sentrum Røntgen Institut AS, Oslo, Norway
- Universitatsklinikum Benjamin Franklin, Berlin, Germany
- Leverkusen, Germany
- Roche (United Kingdom) (GB)
- F. Hoffmann-La Roche AG (CH)
- Lyon 1 Université (FR)
- Corresponding author
- Chesnut, Charles H
- Venue
- Journal of Bone and Mineral Research
- Publisher
- Oxford University Press (OUP)
- Published
- 2004-08-01
- Volume
- 19
- Issue
- 8
- Pages
- 1241-1249
- ISSN
- 0884-0431 (ISSN-L)
- 1523-4681
- OpenAlex
- W2099054178
- Cited by
- 1,229
- References
- 42
- Citations by year
- 2026: 14 · 2025: 38 · 2024: 20 · 2023: 42 · 2022: 31 · 2021: 37 · 2020: 35 · 2019: 32 · 2018: 32 · 2017: 31 · 2016: 43 · 2015: 45 · 2014: 45 · 2013: 63 · 2012: 62
- FWCI
- 85.94
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- academic.oup.com/journals/pages/open_access/funder_policies/chorus/standard_publication_model (vor)
- Locations
- Journal of Bone and Mineral Research (publishedVersion)
- PubMed (publishedVersion)
- Funders
- F. Hoffmann-La Roche
- Topics
- Health Sciences › Medicine › Orthopedics and Sports Medicine › Bone health and osteoporosis research
- Health Sciences › Medicine › Oncology › Bone health and treatments
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Menopause: Health Impacts and Treatments
- Keywords
- ibandronate, intermittent dosing, bisphosphonates, postmenopausal osteoporosis, vertebral fractures, fracture risk reduction, bone mineral density, bone turnover, height loss, drug safety, medication adherence, lumbar spine, hip bone density, antifracture efficacy, treatment discontinuation, adverse events
- MeSH terms
- Ibandronic Acid, Aged, Body Height, Bone and Bones, Diphosphonates, Double-Blind Method, Female, Femur, Humans, Lumbar Vertebrae, Middle Aged, Pelvic Bones, Prospective Studies, Risk Factors, Bone Density, Osteoporosis, Postmenopausal, Spinal Fractures, Treatment Outcome, Patient Selection, Fractures, Bone
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
